Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule

E. S. Casper, Richard J. Gralla, C. W. Young

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aclacinomycin A (ACM) is an anthracycline antibiotic recently introduced into clinical trials because of its reduced cardiac toxicity in animal models relative to Adriamycin and daunomycin. This Phase I study of ACM was conducted to determine a dose suitable for i.v. administration on an every-3-week schedule. Twenty-five adult patients with solid tumors were treated with doses of ACM ranging from 60 to 120 mg/sq m.i.v. every 3 to 4 weeks. Myelosuppression was the dose-limiting toxicity, but the degree and timing of blood count depression were variable at each dose level. Nausea and vomiting were seen at myelosuppressive doses, but mucositis was rare. Alopecia was seen in approximately one-third of the patients. There was no acute cardiac toxicity, but cumulative cardiac injury could not be evaluated in this trial. There were no major objective responses in three patients who had measurable disease. The recommended doses of ACM for Phase II studies are 100 mg/sq m for good-risk patients and 80 mg/sq m for patients who are heavily pretreated or who have a poor performance status.

Original languageEnglish (US)
Pages (from-to)2417-2420
Number of pages4
JournalCancer Research
Volume41
Issue number6
StatePublished - 1981
Externally publishedYes

Fingerprint

Aclarubicin
Intravenous Administration
Appointments and Schedules
Mucositis
Daunorubicin
Anthracyclines
Alopecia
Doxorubicin
Nausea
Vomiting
Animal Models
Clinical Trials
Anti-Bacterial Agents
Wounds and Injuries
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule. / Casper, E. S.; Gralla, Richard J.; Young, C. W.

In: Cancer Research, Vol. 41, No. 6, 1981, p. 2417-2420.

Research output: Contribution to journalArticle

Casper, E. S. ; Gralla, Richard J. ; Young, C. W. / Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule. In: Cancer Research. 1981 ; Vol. 41, No. 6. pp. 2417-2420.
@article{18cb1f55f47947f680efb3351a71d5c5,
title = "Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule",
abstract = "Aclacinomycin A (ACM) is an anthracycline antibiotic recently introduced into clinical trials because of its reduced cardiac toxicity in animal models relative to Adriamycin and daunomycin. This Phase I study of ACM was conducted to determine a dose suitable for i.v. administration on an every-3-week schedule. Twenty-five adult patients with solid tumors were treated with doses of ACM ranging from 60 to 120 mg/sq m.i.v. every 3 to 4 weeks. Myelosuppression was the dose-limiting toxicity, but the degree and timing of blood count depression were variable at each dose level. Nausea and vomiting were seen at myelosuppressive doses, but mucositis was rare. Alopecia was seen in approximately one-third of the patients. There was no acute cardiac toxicity, but cumulative cardiac injury could not be evaluated in this trial. There were no major objective responses in three patients who had measurable disease. The recommended doses of ACM for Phase II studies are 100 mg/sq m for good-risk patients and 80 mg/sq m for patients who are heavily pretreated or who have a poor performance status.",
author = "Casper, {E. S.} and Gralla, {Richard J.} and Young, {C. W.}",
year = "1981",
language = "English (US)",
volume = "41",
pages = "2417--2420",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule

AU - Casper, E. S.

AU - Gralla, Richard J.

AU - Young, C. W.

PY - 1981

Y1 - 1981

N2 - Aclacinomycin A (ACM) is an anthracycline antibiotic recently introduced into clinical trials because of its reduced cardiac toxicity in animal models relative to Adriamycin and daunomycin. This Phase I study of ACM was conducted to determine a dose suitable for i.v. administration on an every-3-week schedule. Twenty-five adult patients with solid tumors were treated with doses of ACM ranging from 60 to 120 mg/sq m.i.v. every 3 to 4 weeks. Myelosuppression was the dose-limiting toxicity, but the degree and timing of blood count depression were variable at each dose level. Nausea and vomiting were seen at myelosuppressive doses, but mucositis was rare. Alopecia was seen in approximately one-third of the patients. There was no acute cardiac toxicity, but cumulative cardiac injury could not be evaluated in this trial. There were no major objective responses in three patients who had measurable disease. The recommended doses of ACM for Phase II studies are 100 mg/sq m for good-risk patients and 80 mg/sq m for patients who are heavily pretreated or who have a poor performance status.

AB - Aclacinomycin A (ACM) is an anthracycline antibiotic recently introduced into clinical trials because of its reduced cardiac toxicity in animal models relative to Adriamycin and daunomycin. This Phase I study of ACM was conducted to determine a dose suitable for i.v. administration on an every-3-week schedule. Twenty-five adult patients with solid tumors were treated with doses of ACM ranging from 60 to 120 mg/sq m.i.v. every 3 to 4 weeks. Myelosuppression was the dose-limiting toxicity, but the degree and timing of blood count depression were variable at each dose level. Nausea and vomiting were seen at myelosuppressive doses, but mucositis was rare. Alopecia was seen in approximately one-third of the patients. There was no acute cardiac toxicity, but cumulative cardiac injury could not be evaluated in this trial. There were no major objective responses in three patients who had measurable disease. The recommended doses of ACM for Phase II studies are 100 mg/sq m for good-risk patients and 80 mg/sq m for patients who are heavily pretreated or who have a poor performance status.

UR - http://www.scopus.com/inward/record.url?scp=0019482631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019482631&partnerID=8YFLogxK

M3 - Article

C2 - 6940656

AN - SCOPUS:0019482631

VL - 41

SP - 2417

EP - 2420

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -